Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives

Gacche, Rajesh N.

doi:10.1016/j.bbcan.2023.189020

Cited by 7 publications

(5 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The binding of VEGF to its receptors triggers a cascade of events leading to the formation of new blood vessels, promoting tumor growth, and facilitating metastasis. As a result, VEGF has become an attractive target for antiangiogenic therapy . Antiangiogenic therapies for colorectal cancer primarily consist of drugs that inhibit VEGF or its receptors.…”

Section: Targeted Therapies In Precision Medicinementioning

confidence: 99%

“…As a result, VEGF has become an attractive target for antiangiogenic therapy. 141 Antiangiogenic therapies for colorectal cancer primarily consist of drugs that inhibit VEGF or its receptors. Bevacizumab, a monoclonal antibody that targets VEGF, is one of the most widely used antiangiogenic agents in the treatment of colorectal cancer.…”

Section: Egfr Inhibitors and Ras Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Section: Targeted Therapies In Precision Medicinementioning

confidence: 99%

Section: Egfr Inhibitors and Ras Pathwaymentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

show abstract

“…Hypoxia indirectly induces effector T-cell apoptosis, also promoting Treg activity, a process counteracted by VEGF inhibition [ 80 ]. Several receptor kinase inhibitors and mAbs have been developed and are currently employed or undergoing clinical trials [ 215 ]. Then, besides inducing tumor vasculature normalization, targeting VEGF can mitigate Treg-mediated apoptosis of intra-tumor effector T cells and has been recognized as a crucial aspect in unraveling the complete potential of ICI blockade, thus holding the potential for improved treatment outcomes [ 216 ].…”

Section: Apoptosis Control To Bypass Immunotherapy Resistancementioning

confidence: 99%

Apoptosis, a Metabolic “Head-to-Head” between Tumor and T Cells: Implications for Immunotherapy

Franzese,

Ancona,

Bianchi

et al. 2024

Cells

View full text Add to dashboard Cite

Induction of apoptosis represents a promising therapeutic approach to drive tumor cells to death. However, this poses challenges due to the intricate nature of cancer biology and the mechanisms employed by cancer cells to survive and escape immune surveillance. Furthermore, molecules released from apoptotic cells and phagocytes in the tumor microenvironment (TME) can facilitate cancer progression and immune evasion. Apoptosis is also a pivotal mechanism in modulating the strength and duration of anti-tumor T-cell responses. Combined strategies including molecular targeting of apoptosis, promoting immunogenic cell death, modulating immunosuppressive cells, and affecting energy pathways can potentially overcome resistance and enhance therapeutic outcomes. Thus, an effective approach for targeting apoptosis within the TME should delicately balance the selective induction of apoptosis in tumor cells, while safeguarding survival, metabolic changes, and functionality of T cells targeting crucial molecular pathways involved in T-cell apoptosis regulation. Enhancing the persistence and effectiveness of T cells may bolster a more resilient and enduring anti-tumor immune response, ultimately advancing therapeutic outcomes in cancer treatment. This review delves into the pivotal topics of this multifaceted issue and suggests drugs and druggable targets for possible combined therapies.

show abstract

“…This normalization of the vasculature shifts suppressive immune conditions to an immune-stimulated state. The activation of the immune system due to therapy also aids in improving the structure of blood vessels, creating a beneficial cycle of mutual enhancement ( 14 ). Therefore, a thorough investigation into the role of angiogenesis in PRAD not only aids in early detection but also holds significant value for immunotherapy in PRAD.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the predictive value of angiogenesis-related genes for prognosis and immunotherapy response in prostate adenocarcinoma using machine learning and experimental approaches

Wang,

He,

Zhao

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAngiogenesis, the process of forming new blood vessels from pre-existing ones, plays a crucial role in the development and advancement of cancer. Although blocking angiogenesis has shown success in treating different types of solid tumors, its relevance in prostate adenocarcinoma (PRAD) has not been thoroughly investigated.MethodThis study utilized the WGCNA method to identify angiogenesis-related genes and assessed their diagnostic and prognostic value in patients with PRAD through cluster analysis. A diagnostic model was constructed using multiple machine learning techniques, while a prognostic model was developed employing the LASSO algorithm, underscoring the relevance of angiogenesis-related genes in PRAD. Further analysis identified MAP7D3 as the most significant prognostic gene among angiogenesis-related genes using multivariate Cox regression analysis and various machine learning algorithms. The study also investigated the correlation between MAP7D3 and immune infiltration as well as drug sensitivity in PRAD. Molecular docking analysis was conducted to assess the binding affinity of MAP7D3 to angiogenic drugs. Immunohistochemistry analysis of 60 PRAD tissue samples confirmed the expression and prognostic value of MAP7D3.ResultOverall, the study identified 10 key angiogenesis-related genes through WGCNA and demonstrated their potential prognostic and immune-related implications in PRAD patients. MAP7D3 is found to be closely associated with the prognosis of PRAD and its response to immunotherapy. Through molecular docking studies, it was revealed that MAP7D3 exhibits a high binding affinity to angiogenic drugs. Furthermore, experimental data confirmed the upregulation of MAP7D3 in PRAD, correlating with a poorer prognosis.ConclusionOur study confirmed the important role of angiogenesis-related genes in PRAD and identified a new angiogenesis-related target MAP7D3.

show abstract

Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives

Cited by 7 publications

References 186 publications

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Apoptosis, a Metabolic “Head-to-Head” between Tumor and T Cells: Implications for Immunotherapy

Evaluating the predictive value of angiogenesis-related genes for prognosis and immunotherapy response in prostate adenocarcinoma using machine learning and experimental approaches

Contact Info

Product

Resources

About